Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odile Launay

Showing results (111-120 of 357) with videos related to

Pageof 36
Sort By:
Human Vaccines & Immunotherapeutics|February 13, 2018
Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritisMathilde Bahuaud, Constance Beaudouin-Bazire, Marine Husson, et al.
European Cytokine Network|December 3, 2016
Production of TNF-alpha ex vivo is predictive of an immune response to flu vaccination in a frail elderly populationFrédéric Bloch, Bénédicte Charmeteau, Michael Tovey, et al.
Vaccine|June 23, 2024
Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method studyAloïs Helary, Elisabeth Botelho-Nevers, Marion Bonneton, et al.
Vaccines|November 27, 2021
Patients' Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of InfectionsPaul Loubet, Jalini Rouvière, Adeline Merceron, et al.
Human Vaccines|November 18, 2008
Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trialJean Beytout, Odile Launay, Nicole Guiso, et al.
Global Health Promotion|May 17, 2013
[Opinions and practices from a panel of French general practitioner doctors regarding vaccination]Sophie Massin, Céline Pulcini, Odile Launay, et al.
Human Vaccines & Immunotherapeutics|October 4, 2012
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuriesHenri Laurichesse, Ulrich Zimmermann, Florence Galtier, et al.
Human Vaccines|September 25, 2010
Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination historySylvie Larnaudie, Nicole Guiso, Charles Baptiste, et al.
Rheumatology (Oxford, England)|December 31, 2009
Low influenza vaccination rate among patients with systemic sclerosisLuc Mouthon, Caroline Mestre, Alice Bérezné, et al.
Obstetrics and Gynecology|August 2, 2008
Maternal biochemical serum screening for Down syndrome in pregnancy with human immunodeficiency virus infectionJean-Patrick Le Meaux, Vassilis Tsatsaris, Thomas Schmitz, et al.
Pageof 36

Showing results (111-120 of 357) with videos related to

Sort By:
Pageof 36
Human Vaccines & Immunotherapeutics|February 13, 2018
Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritisMathilde Bahuaud, Constance Beaudouin-Bazire, Marine Husson, et al.
European Cytokine Network|December 3, 2016
Production of TNF-alpha ex vivo is predictive of an immune response to flu vaccination in a frail elderly populationFrédéric Bloch, Bénédicte Charmeteau, Michael Tovey, et al.
Vaccine|June 23, 2024
Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method studyAloïs Helary, Elisabeth Botelho-Nevers, Marion Bonneton, et al.
Vaccines|November 27, 2021
Patients' Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of InfectionsPaul Loubet, Jalini Rouvière, Adeline Merceron, et al.
Human Vaccines|November 18, 2008
Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trialJean Beytout, Odile Launay, Nicole Guiso, et al.
Global Health Promotion|May 17, 2013
[Opinions and practices from a panel of French general practitioner doctors regarding vaccination]Sophie Massin, Céline Pulcini, Odile Launay, et al.
Human Vaccines & Immunotherapeutics|October 4, 2012
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuriesHenri Laurichesse, Ulrich Zimmermann, Florence Galtier, et al.
Human Vaccines|September 25, 2010
Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination historySylvie Larnaudie, Nicole Guiso, Charles Baptiste, et al.
Rheumatology (Oxford, England)|December 31, 2009
Low influenza vaccination rate among patients with systemic sclerosisLuc Mouthon, Caroline Mestre, Alice Bérezné, et al.
Obstetrics and Gynecology|August 2, 2008
Maternal biochemical serum screening for Down syndrome in pregnancy with human immunodeficiency virus infectionJean-Patrick Le Meaux, Vassilis Tsatsaris, Thomas Schmitz, et al.
Pageof 36